Generali Investments Towarzystwo Funduszy Inwestycyjnych increased its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 33.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,000 shares of the medical research company’s stock after acquiring an additional 6,000 shares during the quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings in Exact Sciences were worth $1,349,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Thompson Investment Management Inc. boosted its position in shares of Exact Sciences by 17.8% during the 4th quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company’s stock valued at $13,585,000 after acquiring an additional 36,505 shares during the last quarter. WCM Investment Management LLC boosted its position in shares of Exact Sciences by 1,153.2% during the 3rd quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company’s stock valued at $12,388,000 after acquiring an additional 172,821 shares during the last quarter. Simplify Asset Management Inc. boosted its position in shares of Exact Sciences by 67.5% during the 3rd quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company’s stock valued at $1,994,000 after acquiring an additional 11,800 shares during the last quarter. Zacks Investment Management acquired a new position in shares of Exact Sciences during the 3rd quarter valued at about $2,083,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Exact Sciences by 59.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company’s stock valued at $22,868,000 after acquiring an additional 125,192 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.
Exact Sciences Stock Down 1.4 %
EXAS stock opened at $47.82 on Friday. The company’s 50 day moving average price is $54.17 and its 200 day moving average price is $59.79. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The firm has a market capitalization of $8.88 billion, a price-to-earnings ratio of -8.59 and a beta of 1.24.
Wall Street Analyst Weigh In
A number of research analysts have commented on the stock. Canaccord Genuity Group decreased their target price on shares of Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 20th. Scotiabank upped their target price on shares of Exact Sciences from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research report on Monday. Jefferies Financial Group upped their target price on shares of Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, Piper Sandler decreased their target price on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Exact Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.94.
Read Our Latest Analysis on EXAS
Exact Sciences Company Profile
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Read More
- Five stocks we like better than Exact Sciences
- Canadian Penny Stocks: Can They Make You Rich?
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- The 3 Best Retail Stocks to Shop for in August
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Why Are These Companies Considered Blue Chips?
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXAS – Free Report).
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.